{
  "docId": "019de073-79f3-7749-b6d9-2feecaaa4d92",
  "docSlug": "3bbd721bd246637706dab09d5c4f3165",
  "documentTitle": "Apexigen | Investor Presentation Deck | 27 slides",
  "authorId": "apexigen",
  "authorName": "Apexigen",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 20,
  "pageCount": 27,
  "prevPage": 19,
  "nextPage": 21,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a two-part structure: a value proposition box followed by a list of upcoming milestones.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-79f3-7749-b6d9-2feecaaa4d92/20",
  "deckHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92",
  "deckJsonHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92.json",
  "deckAnchorHref": "/decks/019de073-79f3-7749-b6d9-2feecaaa4d92#slide-20",
  "components": [
    {
      "bbox": {
        "h": 0.15,
        "w": 0.25,
        "x": 0.05,
        "y": 0.69
      },
      "kind": "callout",
      "text": "Upcoming Milestones",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "79bb5a2e-d257-45fc-bf51-061cd40de0cd",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "callout",
      "text": "Sotigalimab is Potentially the First-in-Class AND Best-in-Class CD40 Agonist Antibody",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8e0d7ba7-feab-4837-b301-c59f1bc2a78e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.6,
        "x": 0.32,
        "y": 0.7
      },
      "kind": "list",
      "text": "Updated Phase 2 esophageal/GEJ data presented at ESMO in Sep 2022; Full enrollment of Phase 2 study in sarcoma patients in H2 2022; Refine design of potential randomized registration-enabling path in PD-1 blockade refractory melanoma",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "82cb1309-4eb1-488a-9a20-1a9a61abae69",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.32,
        "y": 0.28
      },
      "kind": "list",
      "text": "Prospective broad applicability in the treatment of multiple solid tumors; Single-agent anti-tumor effects validate sotigalimab activity; Reasonable safety profile allows combination therapy; Clinical data demonstrate anti-tumor effects; Potential for multiple approval pathways",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b7e19147-e187-46cc-9aca-b520c95a1c33",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.4,
        "x": 0.05,
        "y": 0.08
      },
      "kind": "title",
      "text": "Summary of Sotigalimab Program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0262381a-6d09-428d-88ed-845c1be5dd2c",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "c33b6c54-bbfb-4fb3-b56a-4a9fbc6399e1",
      "evidence": "list/bullet: Prospective broad applicability in the treatment of multiple solid tumors; Single-agent anti-tumor effects validate sotigalimab activity; Reasonable safety profile allows combination therapy; Clinical data d",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "3b7829c3-3966-42d3-a835-880f62f71399",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "Slides 12-20 present various traction metrics, including clinical trial results and partnerships",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}